|
Match
|
Document |
Document Title |
|
|
7378277 |
Methods and compositions for transforming dendritic cells and activating T cells
Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates...
|
|
|
7378089 |
Gene therapy for the prevention of autoimmune disease
Autoimmune disease is treated by the delivery of a suppressive agent to the site of disease. Delivery is accomplished by introducing an expression vector encoding the suppressive agent into cells...
|
|
|
7351409 |
Tumor antigens and CTL clones isolated by a novel procedure
The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE...
|
|
|
7294331 |
Methods of using flt3-ligand in hematopoietic cell transplantation
Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is...
|
|
|
7291450 |
Preparation of a cell concentrate from a physiological solution
The present invention is directed to methods and compositions regarding the preparation of an cell concentrate, such as, for example, an osteogenic cell concentrate, from a physiological solution,...
|
|
|
7288254 |
Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
The invention provides a method of treating diabetes in a subject, comprising administering to the diabetic subject an immunotoxin, thereby reducing the subject's T-cell population, and...
|
|
|
RE39788 |
Gene therapy
Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy.
|
|
|
7232566 |
Methods for treating HIV infected subjects
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the...
|
|
|
7195758 |
Methods of inducing a T cell mediated immune response by administering antigen presenting B cells
We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B...
|
|
|
7175843 |
Methods for selectively stimulating proliferation of T cells
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the...
|
|
|
7166423 |
Direct selection of cells by secretion product
Cells can be labeled with products which they secrete and release in an efficient manner by coupling the cells at their surface to a specific binding partner for the product and allowing the...
|
|
|
7160723 |
Cell separation compositions and methods
The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even...
|
|
|
7144575 |
Methods for selectively stimulating proliferation of T cells
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the...
|
|
|
7122182 |
Oncolytic virus therapy
A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a...
|
|
|
7118924 |
Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents
An improved method for producing human antibodies in SCID mice is provided. The improvement includes the use of dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes...
|
|
|
7115259 |
Use of cytokines and mitogens to inhibit pathological immune responses
The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.
|
|
|
7109183 |
Phosphohalohydrins, process for the production thereof and use thereof
The invention provides compounds comprising at least one phosphohalohydrin group of the formula:
where X is a halogen selected from among I, Br, Cl,
R1 is selected from among —CH 3 ...
|
|
|
7078034 |
In vitro activated γ δ lymphocytes
Patients who develop increased numbers of γδ+ cytotoxic T lymphocytes 2–6 months after allogeneic bone marrow transplantation are less likely to relapse than those who do not. The γδ+ T cells...
|
|
|
7070771 |
Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
This invention relates to genes which encode accessory molecule ligands, such as the CD40 ligand and their use for immunomodulation, vaccination and treatments of various human diseases, including...
|
|
|
7029671 |
Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof
The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts...
|
|
|
6984383 |
Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins
The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains...
|
|
|
6984382 |
Bifunctional protein, preparation and use
A bifunctional protein comprising: 1) a single-chain antibody directed against a suitable antigen on a tumour cell, 2) a hinge region comprising from about 40 to about 200 amino acids joined to the...
|
|
|
6962695 |
Modification of interferon alpha production
A process for the production of α-interferon comprising the steps: i) inducing of human leukocytes by means of a virus; ii) treating the leukocytes with an enhancing agent selected from: a)...
|
|
|
6953573 |
Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The...
|
|
|
6929792 |
Modified dendritic cells and use therefor
The invention provides isolated dendritic cells genetically modified to express a selectin polypeptide, optionally treated with activated platelets or membrane microparticles thereof. The invention...
|
|
|
6926893 |
Multi-stage cascade boosting vaccine
Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising antibodies and anti-idiotype antibodies that mimic an epitope of...
|
|
|
6892140 |
Immunogenic cancer peptides and uses thereof
This invention relates to novel general methods and compositions that provide cancer-specific or highly cancer-associated antigens useful for diagnosis and treatment of cancer.
|
|
|
6838081 |
Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
The present invention provides methods for enhancing the development of APC from precursor cells by administering a combination of GM-CSF and IL-4. The precursor cells include: cells contained in...
|
|
|
6821516 |
Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-γ is increased by about 20 to 30% with respect to standard...
|
|
|
6821513 |
Method for enhancing hematopoiesis
A method is provided for enhancing hematopoiesis. The method includes transplanting at least a therapeutically effective portion of an isolated vascular tissue into a subject, wherein the vascular...
|
|
|
6805861 |
Immunotherapy using cytotoxic T lymphocytes (CTL)
A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain, or are associated with, an abnormal molecule or an abnormally elevated amount of a...
|
|
|
6803036 |
Use of cytokines, cells and mitogens to inhibit graft versus host disease
The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patients that have received allogenic bone marrow transplants.
|
|
|
6759035 |
Method to prevent graft rejection using TGF-beta to induce T suppressor cells
The invention relates to compositions and methods useful for preventing graft rejection in a recipient following organ transplantation.
|
|
|
6747010 |
NKT cell-activating agents containing α-glycosylceramides
An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative...
|
|
|
6716425 |
Method of preventing cancer recurrence
Methods for treating cancer in a mammalian patient having cancer and a functional immune system, and for preventing recurrences of cancer following completion of cancer therapy, are described. The...
|
|
|
6716422 |
Vaccine adjuvants for immunotherapy of melanoma
The invention provides methods of inducing the production of cytolytic T lymphocytes directed against malignancy or infectious agent by a mammal and treating such disease such that deleterious side...
|
|
|
6713056 |
Combined preparation for the treatment of neoplasic diseases or of infectious diseases
The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly...
|
|
|
6692958 |
Cord blood-derived activated lymphocytes, preparations containing said lymphocytes as main ingredient and method and kit for producing said preparations
Activated lymphocytes derived from cord blood are excellently effective for preventing and treating various types of tumors and various types of infection. With interleukin 2 and/or anti-CD3...
|
|
|
6685936 |
Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of suppressor T cells effective to reduce or inhibit host rejection of the...
|
|
|
6682731 |
Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
|
|
|
6669965 |
Method of treating atherosclerosis
A method of treating or preventing atherosclerosis in a mammalian subject comprises: (a) extracting the aliquot of blood from the subject; (b) treating the aliquot of blood ex vivo with at least...
|
|
|
6663859 |
Compositions for enhancing the immune response
D-Ribose and methods for using D-Ribose are provided for enhancing the immune response in mammals. Those with a less than optimal immune response will benefit from oral or parenteral administration...
|
|
|
6660723 |
Phosphalohydrins and methods for medicinal administration
The invention provides compounds comprising at least one phosphohalohydrin group of the formula: where X is a halogen selected from among I, Br, Cl, R1 is selected from among —CH 3 and —CH...
|
|
|
6638512 |
Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens
A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection...
|
|
|
6613320 |
Defective CD4&plus T-cells that express active CD40-L
CD4 + cells obtained from individuals with defective CD40L gene and transfected with a vector containing CD40-L are described.
|
|
|
6602510 |
HLA class I A2 tumor associated antigen peptides and vaccine compositions
A composition or vaccine composition comprising eight isolated epitopes consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2), KLBPVQLWV (SEQ. ID. NO: 3), SMPPPGTRV (SEQ. ID. NO: 4),...
|
|
|
6596275 |
Monocyte derived cells with immunosuppressive properties, process for their preparation and their uses in pharmaceutical compositions
Monocyte derived cells with immunosuppressive properties including an increase in at least one of the following PGE-2, IL-10 and IL-4. Monocyte derived cells with a decreased level of expression...
|
|
|
6589526 |
Enrichment of dendritic cells from blood
A method for the enrichment of dendritic cells from the peripheral blood of a mammal is described. Peripheral blood having mononuclear cells from a mammal is provided. The mononuclear cells are...
|
|
|
6576466 |
Tumoricidal T lymphocytes
The present invention concerns a mammalian cell line which when co-cultured with lymphocytes during which allogenic stimulation is avoided activates lymphocytes fo form tumoricidal cells, a process...
|
|
|
6562334 |
Canine interleukin 12 administration as an immune disease treatment
Canine interleukin 12 and a method for producing it by genetic engineering are disclosed. The canine interleukin 12 includes a protein having an amino acid sequence substantially the same as SEQ ID...
|